Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Merck
McKesson
Medtronic
Boehringer Ingelheim

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,343,995

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,343,995 protect, and when does it expire?

Patent 10,343,995 protects YUPELRI and is included in one NDA.

This patent has thirty-six patent family members in twenty-six countries.

Summary for Patent: 10,343,995
Title:Biphenyl compounds useful as muscarinic receptor antagonists
Abstract: This invention provides compounds of formula I: ##STR00001## wherein a, b, c, d, m, n, p, s, t, W, Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, and R.sup.8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Inventor(s): Mammen; Mathai (Menlo Park, CA), Ji; YuHua (Palo Alto, CA), Mu; YongQi (Los Altos, CA), Husfeld; Craig (Redwood City, CA), Li; Li (Sunnyvale, CA)
Assignee: THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)
Application Number:16/130,076
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 10,343,995

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mylan Ireland Ltd YUPELRI revefenacin SOLUTION;INHALATION 210598-001 Nov 9, 2018 RX Yes Yes   Start Trial   Start Trial FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,343,995

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 048032   Start Trial
Argentina 104444   Start Trial
Austria 395335   Start Trial
Austria 467617   Start Trial
Australia 2005222411   Start Trial
Brazil PI0508622   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Harvard Business School
McKinsey
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.